This assignment is a summary of a news article from Google News and is focused on the search term, “New Treatment.” After entering this term into the search, I found one FDA article about the new treatment launched for a very rare disease condition named ADL, or amyotrophic lateral sclerosis (ALS). In this condition, the coordination ability of muscles is affected, and there is no cure currently in the world. This discovery of Relyvio against ALS-like rare disease conditions will be highly recommended to overcome it. Around 20,000 people in the country suffer from it and live their lives until death (U.S. Food and Drug Administration, 2022). A better medical system will ease the pain and improve the quality of life for this population. But the researchers had identified this drug combination under the trade name, Relyvrio, as effective against ALS. There had been a trial conducted for this drug on around 137 patients suffering from ALS and it was found that it had decreased the rate of decline of disease condition in them compared to placebo participants.
The main constituent of this drug combination is taurursodiol, which is a bile acid, and it is mainly responsible for the adverse effects associated with it. As side effects of this medication, patients reported upper respiratory tract infection, nausea, diarrhea, and abdominal pain. The most important precaution with Relyvrio is to avoid prescribing it to patients with liver disease or kidney failure as it affects bile acid circulation and increases its availability in the circulatory system. This research was necessary and also suggested by future research as around 5000 Americans reported this medical condition ending in death due to respiratory failure and other muscle-dependent organ failures (U.S. Food and Drug Administration, 2022). Amylyx Pharmaceuticals Inc. is a company that has received a grant from the FDA for Relyvrio and has been placed in orphan drug designation.
FDA Approves New Treatment Option for Patients with ALS. U.S. Food and Drug Administration. (2022). https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-als.